Perspective Therapeutics, Inc. short interest in 2023
In 2023, Perspective Therapeutics, Inc.'s disclosed short interest ran from 0.29% of shares outstanding on 13 Jan 2023 to 0.69% on 29 Dec 2023, a change of +0.40 percentage points. The year's high was 0.91% on 28 Apr 2023 and its low 0.19% on 15 Feb 2023, averaging 0.60% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.12 days on 14 Jul 2023. Full history: Perspective Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.29% (13 Jan 2023)
- End of year
- 0.69% (29 Dec 2023)
- Change
- +0.40 pp
- High
- 0.91% (28 Apr 2023)
- Low
- 0.19% (15 Feb 2023)
- Average
- 0.60%
- Highest days to cover
- 10.12 (14 Jul 2023)
- SEC filings marked
- 6
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.29% | 2.11 | |
| 31 Jan 2023 | 0.29% | 1.47 | |
| 15 Feb 2023 | 0.19% | 1.00 | |
| 28 Apr 2023 | 0.91% | 5.06 | results (8-K) |
| 15 May 2023 | 0.69% | 5.13 | 10-Q filed |
| 31 May 2023 | 0.64% | 3.76 | |
| 15 Jun 2023 | 0.56% | 6.57 | |
| 30 Jun 2023 | 0.61% | 3.54 | |
| 14 Jul 2023 | 0.59% | 10.12 | |
| 31 Jul 2023 | 0.61% | 9.04 | |
| 15 Aug 2023 | 0.63% | 4.60 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 0.56% | 4.10 | |
| 15 Sep 2023 | 0.56% | 5.60 | |
| 29 Sep 2023 | 0.72% | 1.00 | |
| 13 Oct 2023 | 0.69% | 6.31 | |
| 31 Oct 2023 | 0.73% | 6.55 | |
| 15 Nov 2023 | 0.69% | 6.14 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 0.66% | 7.59 | |
| 15 Dec 2023 | 0.64% | 4.84 | |
| 29 Dec 2023 | 0.69% | 1.31 |
See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.